These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 19950573)

  • 1. [Chromosome 13q deletion detected by interphase FISH in multiple myeloma: a study of 100 cases in China].
    Li Q; Lu Y; Wang YF; Liu XP; Qi JY; Zou DH; Zhao YZ; Qiu LG
    Zhonghua Yi Xue Za Zhi; 2009 Jul; 89(28):1979-82. PubMed ID: 19950573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cytogenetic characteristics of patients with multiple myeloma in China: analysis of 100 case].
    Deng SH; Xu Y; Wang YF; Mai YJ; Liu XP; Zhao YZ; Zou DH; Wang Y; Qiu LG
    Zhonghua Yi Xue Za Zhi; 2007 Jun; 87(24):1685-8. PubMed ID: 17825148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
    Fonseca R; Harrington D; Oken MM; Dewald GW; Bailey RJ; Van Wier SA; Henderson KJ; Blood EA; Rajkumar SV; Kay NE; Van Ness B; Greipp PR
    Cancer Res; 2002 Feb; 62(3):715-20. PubMed ID: 11830525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The significances of 13q14 deletion for development and prognosis of multiple myeloma].
    Li Q; An G; Li CW; Xu Y; Deng SH; Liu XP; Qi JY; Wang YF; Zou DH; Zhao YZ; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):217-20. PubMed ID: 21569701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia.
    Rasillo A; Tabernero MD; Sánchez ML; Pérez de Andrés M; Martín Ayuso M; Hernández J; Moro MJ; Fernández-Calvo J; Sayagués JM; Bortoluci A; San Miguel JF; Orfao A
    Cancer; 2003 Feb; 97(3):601-9. PubMed ID: 12548602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of undetermined significance without and with positive plasma cell identification: analysis of 192 cases from the Region of Southern Denmark.
    Christensen JH; Abildgaard N; Plesner T; Nibe A; Nielsen O; Sørensen AG; Kerndrup GB;
    Cancer Genet Cytogenet; 2007 Apr; 174(2):89-99. PubMed ID: 17452249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection of deletion of the long arm of chromosome 13 and translocation of immunoglobulin heavy chain gene by interphase fluorescence in situ hybridization in patients with multiple myeloma].
    Sun WL; Wu YJ; Li H; Wang X; Zhuang JL
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2008 Aug; 30(4):485-90. PubMed ID: 18795626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma.
    Chiecchio L; Protheroe RK; Ibrahim AH; Cheung KL; Rudduck C; Dagrada GP; Cabanas ED; Parker T; Nightingale M; Wechalekar A; Orchard KH; Harrison CJ; Cross NC; Morgan GJ; Ross FM
    Leukemia; 2006 Sep; 20(9):1610-7. PubMed ID: 16826223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
    Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
    Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
    Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
    Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation between chromosome 13q14 deletion and 1q abnormality in multiple myeloma].
    Chen LJ; Li JY; Zhu Y; Wang XW; Qiu HR; Yang RF; Xu W; Xu JR; Lu H
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Feb; 26(1):102-5. PubMed ID: 19199264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Chang H; Qi X; Jiang A; Xu W; Young T; Reece D
    Bone Marrow Transplant; 2010 Jan; 45(1):117-21. PubMed ID: 19448682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting plasma cells improves detection of cytogenetic aberrations in multiple myeloma: phenotype/genotype fluorescence in situ hybridization.
    Slovak ML; Bedell V; Pagel K; Chang KL; Smith D; Somlo G
    Cancer Genet Cytogenet; 2005 Apr; 158(2):99-109. PubMed ID: 15796956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.
    Lai YY; Huang XJ; Cai Z; Cao XS; Chen FP; Chen XQ; Chen BA; Fang MY; Feng JF; Fu WL; Guo HY; Hou M; Hou J; Hu Y; Hu XT; Hu XM; Huang LQ; Jin J; Li JY; Li J; Li W; Liang YM; Liu T; Liu QF; Liu YH; Mao P; Ouyang J; Qiu LG; Qiu L; Shao CK; Shi B; Song YP; Sun ZM; Wang QS; Wang C; Wang JM; Wang YS; Wang Z; Wu JB; Wu YX; Xia RX; Xue YQ; Yang BZ; Yang G; Yang ZL; Yu L; Yuan Z; Zhang S; Zhang Y; Zhao HG; Zhao L; Zhou DB; Zou SH; Zhu YF
    Chin Med J (Engl); 2012 Aug; 125(15):2663-70. PubMed ID: 22931972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low p27Kip1 expression is an independent adverse prognostic factor in patients with multiple myeloma.
    Filipits M; Pohl G; Stranzl T; Kaufmann H; Ackermann J; Gisslinger H; Greinix H; Chott A; Drach J
    Clin Cancer Res; 2003 Feb; 9(2):820-6. PubMed ID: 12576455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: a combined morphology and I-FISH analysis.
    Koren-Michowitz M; Hardan I; Berghoff J; Yshoev G; Amariglio N; Rechavi G; Nagler A; Trakhtenbrot L
    Cancer Lett; 2007 Oct; 255(2):307-14. PubMed ID: 17590504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High incidence and intraclonal heterogeneity of chromosome 11 aberrations in patients with newly diagnosed multiple myeloma detected by multiprobe interphase FISH.
    Cremer FW; Kartal M; Hose D; Bila J; Buck I; Bellos F; Raab MS; Brough M; Moebus A; Hager HD; Goldschmidt H; Moos M; Bartram CR; Jauch A
    Cancer Genet Cytogenet; 2005 Sep; 161(2):116-24. PubMed ID: 16102581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
    Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The analysis of prognostic variables in 123 patients with multiple myeloma].
    Xu Y; Deng SH; Mai YJ; Li X; Qi PJ; Zhao YZ; Zou DH; Wang YF; Qian LS; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):330-4. PubMed ID: 17877163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of standard prognostic factors with the deletion of 13q14 detected by interphase fluorescence in situ hybridization on separated and unseparated bone marrow cells in multiple myeloma].
    Smejkalová J; Vranová V; Oltová A; Kuglík P; Filková H; Heinigová J; Kovárová L; Adam Z; Krejcí M; Pour L; Büchler T; Svobodník A; Vostrejsová S; Kalábová V; Vorlícek J; Penka M; Hájek R
    Cas Lek Cesk; 2005; 144(7):483-8. PubMed ID: 16161543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.